Developing a Validated HPLC Method for Quantification of Ceftazidime Employing Analytical Quality by Design and Monte Carlo Simulations

Abstract

Background Ceftazidime, a third-generation cephalosporin, is widely used in the treatment of lung infections, often given as “off-label” nebulization. There is need for developing a sensitive and robust analytical method to compute aerodynamic properties of ceftazidime following nebulization. Objective The current study entails development of a simple, accurate and sensitive high-performance liquid chromatography method (HPLC) for ceftazidime estimation, employing the principles of analytical quality-by-design (AQbD) and Monte Carlo simulations. Methods Selection of critical material attributes (CMAs) affecting method performance was accomplished by factor screening exercise. Subsequently, the influential CMAs, i.e., mobile phase ratio and flow rate, were systemically optimized using a face-centred cubic design for the chosen critical analytical attributes (CAAs). The factor relationship(s) between CMAs and CAAs was explored employing 3 D-response surface and 2 D-contour plots, followed by numerical as well as graphical optimization, for establishing the optimal chromatographic conditions. The obtained method operable design region was validated by Monte Carlo simulations for defect rate analysis. Results The optimized HPLC conditions for estimating ceftazidime were acetonitrile to acetic acid solution (75:25) as mobile phase at a flow rate of 0.7 mL/min, leading to Rt of 4.5 min and peak tailing ≤ 2. Validation studies, as per ICH Q2(R1) guidance’s, demonstrated high sensitivity, accuracy and efficiency of the developed analytical method with LOD of 0.075 and LOQ of 0.227 µg/mL. Application of this chromatographic method was extrapolated for determining aerodynamic performance by nebulizing ceftazidime at flow rate of 15 L/min using next-generation impactor. The study indicated superior performance, sensitivity and specificity of the developed analytical system for quantifying ceftazidime. Conclusions Application of AQbD approach, coupled with Monte Carlo simulations, aided in developing a robust HPLC method for estimation of ceftazidime per se and on various stages of impactor.

Hansen Solubility Parameters and QbD-Oriented HPLC Method Development and Validation for Dermatokinetic Study of a Miconazole-Loaded Cationic Nanoemulsion in Rat Model

“…The two factors at three levels expressed as Y (response) = (3) against two responses were employed in Design Expert (Stat-Ease Inc., 1300 Godward St NE #6400, Minneapolis, Minneapolis 55413) to investigate the impact of the selected factors (from HSPiP and Taguchi model) on the targeted responses (retention time as Y 1 and peak area as Y 2 ). These two factors significantly influence responses/attributes for the development of robust bioanalytical method for quantification of MCZ in plasma by optimizing ACN concentration at the explored working conditions. − The target goals were minimum and maximum for Y 1 and Y 2 , respectively. Eq includes the studied factors ( X 1 and X 2 ) and coefficients (β 1 , β 2 , β 0 , β 3 , β 4 , and β 5 ) to understand the impact of the factors on the respective response, wherein negative and positive terms indicate the antagonistic and synergistic effect on the response, respectively. Y ( independent variable ) = β 0 + β 1 X 1 + β 2 X 2 + β 3 X 1 X 2 + β 4 X 1 2 + β 5 X 2 2 where β 0 , β 1 , and β 2 are the intercept, the coefficient of X 1 , and the coefficient of X 2 , respectively.…”

Stability Indicating Assay for the Determination of Bilastine in Bulk Drug and Method Development Validation by RP-HPLC Using Analytical Quality by Design Approaches

“…18,19 Robustness: Robustness studies were performed by changing method parameters in system such as Flow rate (±0.1%), Ph (±0.1) and Composition of mobile phase (±5%). [20][21][22] Forced Degradation Studies 23-25…”